What is the difference between Soliqua and Xultophy?

Soliqua 100/33 is Sanofi’s once-daily injection used alongside diet and exercise to improve blood sugar control in type 2 diabetes.

Soliqua 100/33 is a combination of insulin glargine 100 Units/mL (Lantus) and lixisenatide 33 mcg/mL (Adlyxin), a glucagon-like peptide-1 (GLP-1) agonist, for patients inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide.

Xultophy 100/3.6 is Novo Nordisk’s once-daily injection of insulin degludec (Tresiba), and the GLP-1 agonist liraglutide (Victoza), also used to treat type 2 diabetes.

Xultophy is used in adults inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily.

These two medications are the first approved in a novel group of diabetes treatments that combine a long-acting insulin with a GLP-1 agonist.